<br>        Inclusion Criteria:<br><br>          -  Age 18- 42 (upon starting COH);<br><br>          -  BMI <30 kg/m2;<br><br>          -  <3 prior ART cycles (IVF, ICSI and related procedures);<br><br>          -  Baseline (day 2-3 of cycling) FSH <15 IU/L and E2 <80 pg/mL;<br><br>          -  Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or<br>             hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid);<br><br>          -  At least 3 retrieved oocytes;<br><br>          -  Patient has given written informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Intramural uterine fibroids that distort the uterine cavity or polyps >1 cm;<br><br>          -  Stage III or IV endometriosis (endometriomas);<br><br>          -  Hydrosalpinx;<br><br>          -  History of past poor response to COH resulting in canceling ART;<br><br>          -  Use of thawed/donated oocytes;<br><br>          -  Use of thawed/donated embryos;<br><br>          -  Patients affected by pathologies associated with any contraindication of being<br>             pregnant;<br><br>          -  Hypersensitivity to study medication;<br><br>          -  Uncontrolled adrenal or thyroid dysfunction;<br><br>          -  Undiagnosed vaginal bleeding;<br><br>          -  History of arterial disease;<br><br>          -  Patients with hepatic impairment;<br><br>          -  Neoplasias (current) or history of neoplasia that may be responsive to progesterone;<br><br>          -  High grade cervical dysplasia;<br><br>          -  Active thrombophlebitis or thromboembolic disorders, or a history of<br>             hormone-associated thrombophlebitis or thromboembolic disorders;<br><br>          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages<br>             wherein pregnancy developed to a minimum of a gestational sac on TVUS;<br><br>          -  Participation in a concurrent clinical trial or another trial within the past 2<br>             months;<br><br>          -  Use of concomitant medications that might interfere with the study evaluation;<br><br>          -  Pre-implantation genetic diagnosis/screening.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Age 18- 42 (upon starting COH);<br><br>          -  BMI <30 kg/m2;<br><br>          -  <3 prior ART cycles (IVF, ICSI and related procedures);<br><br>          -  Baseline (day 2-3 of cycling) FSH <15 IU/L and E2 <80 pg/mL;<br><br>          -  Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or<br>             hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid);<br><br>          -  At least 3 retrieved oocytes;<br><br>          -  Patient has given written informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Intramural uterine fibroids that distort the uterine cavity or polyps >1 cm;<br><br>          -  Stage III or IV endometriosis (endometriomas);<br><br>          -  Hydrosalpinx;<br><br>          -  History of past poor response to COH resulting in canceling ART;<br><br>          -  Use of thawed/donated oocytes;<br><br>          -  Use of thawed/donated embryos;<br><br>          -  Patients affected by pathologies associated with any contraindication of being<br>             pregnant;<br><br>          -  Hypersensitivity to study medication;<br><br>          -  Uncontrolled adrenal or thyroid dysfunction;<br><br>          -  Undiagnosed vaginal bleeding;<br><br>          -  History of arterial disease;<br><br>          -  Patients with hepatic impairment;<br><br>          -  Neoplasias (current) or history of neoplasia that may be responsive to progesterone;<br><br>          -  High grade cervical dysplasia;<br><br>          -  Active thrombophlebitis or thromboembolic disorders, or a history of<br>             hormone-associated thrombophlebitis or thromboembolic disorders;<br><br>          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages<br>             wherein pregnancy developed to a minimum of a gestational sac on TVUS;<br><br>          -  Participation in a concurrent clinical trial or another trial within the past 2<br>             months;<br><br>          -  Use of concomitant medications that might interfere with the study evaluation;<br><br>          -  Pre-implantation genetic diagnosis/screening.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Age 18- 42 (upon starting COH);<br><br>          -  BMI <30 kg/m2;<br><br>          -  <3 prior ART cycles (IVF, ICSI and related procedures);<br><br>          -  Baseline (day 2-3 of cycling) FSH <15 IU/L and E2 <80 pg/mL;<br><br>          -  Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or<br>             hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid);<br><br>          -  At least 3 retrieved oocytes;<br><br>          -  Patient has given written informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Intramural uterine fibroids that distort the uterine cavity or polyps >1 cm;<br><br>          -  Stage III or IV endometriosis (endometriomas);<br><br>          -  Hydrosalpinx;<br><br>          -  History of past poor response to COH resulting in canceling ART;<br><br>          -  Use of thawed/donated oocytes;<br><br>          -  Use of thawed/donated embryos;<br><br>          -  Patients affected by pathologies associated with any contraindication of being<br>             pregnant;<br><br>          -  Hypersensitivity to study medication;<br><br>          -  Uncontrolled adrenal or thyroid dysfunction;<br><br>          -  Undiagnosed vaginal bleeding;<br><br>          -  History of arterial disease;<br><br>          -  Patients with hepatic impairment;<br><br>          -  Neoplasias (current) or history of neoplasia that may be responsive to progesterone;<br><br>          -  High grade cervical dysplasia;<br><br>          -  Active thrombophlebitis or thromboembolic disorders, or a history of<br>             hormone-associated thrombophlebitis or thromboembolic disorders;<br><br>          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages<br>             wherein pregnancy developed to a minimum of a gestational sac on TVUS;<br><br>          -  Participation in a concurrent clinical trial or another trial within the past 2<br>             months;<br><br>          -  Use of concomitant medications that might interfere with the study evaluation;<br><br>          -  Pre-implantation genetic diagnosis/screening.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Age 18- 42 (upon starting COH);<br><br>          -  BMI <30 kg/m2;<br><br>          -  <3 prior ART cycles (IVF, ICSI and related procedures);<br><br>          -  Baseline (day 2-3 of cycling) FSH <15 IU/L and E2 <80 pg/mL;<br><br>          -  Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or<br>             hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid);<br><br>          -  At least 3 retrieved oocytes;<br><br>          -  Patient has given written informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Intramural uterine fibroids that distort the uterine cavity or polyps >1 cm;<br><br>          -  Stage III or IV endometriosis (endometriomas);<br><br>          -  Hydrosalpinx;<br><br>          -  History of past poor response to COH resulting in canceling ART;<br><br>          -  Use of thawed/donated oocytes;<br><br>          -  Use of thawed/donated embryos;<br><br>          -  Patients affected by pathologies associated with any contraindication of being<br>             pregnant;<br><br>          -  Hypersensitivity to study medication;<br><br>          -  Uncontrolled adrenal or thyroid dysfunction;<br><br>          -  Undiagnosed vaginal bleeding;<br><br>          -  History of arterial disease;<br><br>          -  Patients with hepatic impairment;<br><br>          -  Neoplasias (current) or history of neoplasia that may be responsive to progesterone;<br><br>          -  High grade cervical dysplasia;<br><br>          -  Active thrombophlebitis or thromboembolic disorders, or a history of<br>             hormone-associated thrombophlebitis or thromboembolic disorders;<br><br>          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages<br>             wherein pregnancy developed to a minimum of a gestational sac on TVUS;<br><br>          -  Participation in a concurrent clinical trial or another trial within the past 2<br>             months;<br><br>          -  Use of concomitant medications that might interfere with the study evaluation;<br><br>          -  Pre-implantation genetic diagnosis/screening.<br>